|
|
| | INCB-047775 Basic information |
| Product Name: | INCB-047775 | | Synonyms: | INCB-047775;1H-Pyrazole-4-carbonitrile, 5-[2-[(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-1-methyl-;AKT-IN-6;AKT IN 6,AKTIN6;AKT-IN-6, 10 mM in DMSO;(S)-5-(2-(1-amino-3-(3-fluorophenyl)propan-2-yl)-1-oxoisoindolin-5-yl)-1-methyl-1H-pyrazole-4-carbonitrile | | CAS: | 1430056-54-4 | | MF: | C22H20FN5O | | MW: | 389.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1430056-54-4.mol |  |
| | INCB-047775 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (320.98 mM; Need ultrasonic) | | form | Solid | | color | Yellow to brown |
| | INCB-047775 Usage And Synthesis |
| Uses | AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1). | | Biological Activity | AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).
Akt is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer[2]. | | IC 50 | Akt1; Akt2; Akt3 | | References | [1]. Taisheng Huang; et al.Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors. WO2013056015A1. [2]. Manning BD, et al. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274. |
| | INCB-047775 Preparation Products And Raw materials |
|